BioMarin Pharmaceutical Inc. (BMRN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BMRN Revenue Growth
Revenue Breakdown (FY 2025)
BMRN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BMRN Revenue Analysis (2014–2025)
As of May 7, 2026, BioMarin Pharmaceutical Inc. (BMRN) generated trailing twelve-month (TTM) revenue of $3.24 billion, reflecting modest growth of +2.8% year-over-year. The most recent quarter (Q1 2026) recorded $766.2 million in revenue, down 12.4% sequentially.
Looking at the longer-term picture, BMRN's 5-year compound annual growth rate (CAGR) stands at +11.6%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $3.22 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows BMRN's business is primarily driven by Product (98%), and Royalty And Other (2%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RARE (+13.3% YoY), SRPT (-2.2% YoY), and IONS (+47.5% YoY), BMRN has underperformed the peer group in terms of revenue growth. Compare BMRN vs RARE →
BMRN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BMRNCurrent | $3.2B | +2.8% | +11.6% | 16.6% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 ACAD | $1.1B | +11.9% | +19.4% | 9.8% | |
 FOLD | $528M | +21.3% | +23.7% | 4.7% |
BMRN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.22B | +12.9% | $2.48B | 77.1% | $533.5M | 16.6% |
| 2024 | $2.85B | +18.0% | $2.27B | 79.7% | $484.2M | 17.0% |
| 2023 | $2.42B | +15.4% | $1.89B | 78.0% | $185.8M | 7.7% |
| 2022 | $2.10B | +13.5% | $1.59B | 76.0% | $161.0M | 7.7% |
| 2021 | $1.85B | -0.8% | $1.38B | 74.5% | $-82,341,000 | -4.5% |
| 2020 | $1.86B | +9.2% | $1.34B | 71.8% | $-43,440,000 | -2.3% |
| 2019 | $1.70B | +14.3% | $1.34B | 78.9% | $-100,457,000 | -5.9% |
| 2018 | $1.49B | +13.5% | $1.18B | 78.9% | $-123,524,000 | -8.3% |
| 2017 | $1.31B | +17.6% | $1.07B | 81.6% | $-14,700,000 | -1.1% |
| 2016 | $1.12B | +25.5% | $907.2M | 81.2% | $-803,429,000 | -71.9% |
Full BMRN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BMRN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMRN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BMRN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBMRN — Frequently Asked Questions
Quick answers to the most common questions about buying BMRN stock.
Is BMRN's revenue growth accelerating or slowing?
BMRN revenue growth slowed to +2.8%, below the 5-year CAGR of +11.6%. TTM revenue is $3.2B. The deceleration marks a shift from historical growth rates.
What is BMRN's long-term revenue growth rate?
BioMarin Pharmaceutical Inc.'s 5-year revenue CAGR of +11.6% reflects the variable expansion pattern. Current YoY growth of +2.8% is near this long-term average.
How is BMRN's revenue distributed by segment?
BMRN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.